Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
1.79 USD -5.79% Intraday chart for Ocean Biomedical, Inc. -27.53% +171.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ocean Biomedical, Inc. Appoints Amy Griffith as Director CI
Ocean Biomedical, Inc. Announces CFO Changes CI
North American Morning Briefing : S&P 500 Futures -2- DJ
North American Morning Briefing : Central Bankers -2- DJ
North American Morning Briefing : Stocks to -2- DJ
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight DJ
North American Morning Briefing : Traders Await -2- DJ
Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 Antibody CI
Ocean Biomedical Receives Non-Compliance Notice From Nasdaq MT
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading DJ
Ocean Biomedical Says Potential Treatment for Advanced Solid Tumors Yields 'Highly Compelling' Preclinical Data MT
Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics CI
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical Announces First Patients Dosed with Novel Immunotherapy Evaluating A Functional Cure for Chronic Hepatitis B Virus Infection CI
Ocean Biomedical, Inc. Announces Resignation of Jerome Ringo as Member of Board of Directors CI
Ocean Biomedical, Virion Therapeutics Form Joint Venture to Seek Cures for Cancer, Infectious Diseases MT
Ocean Biomedical, Inc. announced that it expects to receive $10 million in funding from Poseidon Bio, LLC CI
Ocean Biomedical Says Data Show Antibody Candidate Can Restore Treatment Sensitivity to AstraZeneca's Lung Cancer Drug MT
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to Astrazeneca?s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers CI
Ocean Biomedical Secures US Patent for Anti-Chitinase 1 Small Molecule Candidate MT
Ocean Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ocean Biomedical, Inc. Provides Latest Updates on Its Broad Programs in Malaria, Fibrosis, and Multiple Cancers CI
Ocean Biomedical Says Vaccine Candidate Led to Over 90% Killing of Malaria Parasites in Non-Human Primates MT
Chart Ocean Biomedical, Inc.
More charts
Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
More about the company
  1. Stock Market
  2. Equities
  3. OCEA Stock
  4. News Ocean Biomedical, Inc.
  5. Ocean Biomedical Says Potential Treatment for Advanced Solid Tumors Yields 'Highly Compelling' Preclinical Data